Patients whose type 2 diabetes (T2D) remains persistently poorly-controlled despite receiving clinic-based care are at high risk for complications and costs. To address clinic-refractory T2D within the Veterans Health Administration, we conducted a randomized trial comparing two nurse-delivered telehealth strategies to augment clinic-based care: 1) telemonitoring and care coordination; and 2) a comprehensive intervention combining telemonitoring, self-management support, diet/activity support, medication management, and depression management. Delivery of both interventions utilized only existing clinical staff and infrastructure. Patients (n=200) with HbA1c continually ≥8.5% for ≥1 year despite receiving diabetes management from Primary Care and/or Endocrinology were randomized in a 1:1 ratio to the two 12-month intervention arms between 12/2018 and 1/2020. We analyzed our primary outcome, HbA1c collected at 0, 3, 6, 9 and 12 months, using linear mixed models. Secondary outcomes included BMI and hypoglycemia. Patients had a mean age of 58, and were mostly male (78%) and African American (72%); all patients were engaged with Primary Care prior to enrollment, and 68% with Endocrinology. Baseline characteristics were similar across arms. Estimated mean baseline HbA1c was 10.08%, which declined to an estimated 9.23% at 12 months in the telemonitoring arm and 8.67% in the comprehensive telehealth arm (estimated between-arm difference at 12 months -0.55%, 95%CI -1.06%,-0.05%, p=0.03). No difference in BMI between arms was seen. Hypoglycemia rates were low, and similar between arms. While both strategies improved HbA1c in this high-risk, clinic-refractory population, the comprehensive telehealth intervention led to a clinically and statistically significant added HbA1c benefit. Because its delivery relies solely on existing clinical resources, this comprehensive intervention may be a practical means to address clinic-refractory T2D.

Disclosure

M. J. Crowley: None. D. H. Jeter: None. E. Strawbridge: None. T. C. Wilmot: None. G. A. Tisdale: None. T. Marcano: None. D. L. Overby: None. M. A. Durkee: None. S. Bullard: None. M. Dar: None. A. Mundy: None. P. E. Tarkington: Stock/Shareholder; Self; Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson. S. T. Szabo: None. S. Desai: None. E. A. Kobe: None. N. Majette elliott: None. D. Edelman: None. H. B. Bosworth: Board Member; Self; Preventric Diagnostics, LLC., Consultant; Self; Novartis Pharmaceuticals Corporation, VIDYA, Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Improved Patient Outcomes, Novo Nordisk, Otsuka America Pharmaceutical, Inc., Sanofi. M. L. Maciejewski: Employee; Spouse/Partner; Amgen Inc., Stock/Shareholder; Spouse/Partner; Amgen Inc. K. Steinhauser: None. A. S. Jeffreys: None. C. Coffman: None. V. Smith: None. S. Danus: None.

Funding

U.S. Department of Veterans Affairs (IIR 16-213); Durham Veterans Affairs Center of Innovation to Accelerate Discovery and Practice Transformation (CIN 13-410)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.